Ipamorelin
A selective growth hormone secretagogue (ghrelin receptor agonist) that stimulates pituitary GH release without significantly elevating cortisol or prolactin — considered the cleanest GH peptide available.
Mechanism of Action
Acts as a selective agonist of the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. Stimulates endogenous GH release while preserving normal pulsatile GH secretion patterns. Uniquely selective — does not significantly stimulate ACTH, cortisol, or prolactin release unlike other GHRP peptides. Downstream effects mediated through the GH/IGF-1 axis.
Typical Dosing
⚠ Warning Flags
- •Mild water retention possible
- •Mild appetite increase
- •Best used in combination with CJC-1295 for synergistic GH release
Effect Profile
Side Effect Profile
Research Studies
Ipamorelin, the first selective growth hormone secretagogue
Raun K et al. · 1998
Demonstrated that Ipamorelin selectively stimulates GH release without increasing cortisol or prolactin — unique among GH secretagogues.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Gobburu JV et al. · 1999
Characterized the dose-response pharmacokinetics of Ipamorelin GH secretion in healthy humans.
Growth hormone-releasing peptide (GHRP)
Bowers CY · 2012
Comprehensive review of growth hormone secretagogues and their clinical effects on the somatotropic axis.